Hyperion Therapeutics (HPTX) Files $57.5M IPO
Tweet
Share
E-mailGet Alerts HPTX Hot Sheet
Join SI Premium – FREE
Hyperion Therapeutics (Nasdaq: HPTX) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $57.5 million. Hyperion plans to list on the Nasdaq Global Market under the ticker "HPTX."
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMR Resources prices $250M IPO on Nasdaq at $10 per unit
- Laser Photonics to raise $2.5M through warrant exercise
- Vireo Growth completes $20M Pennsylvania dispensary license deal
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
